Hepatectomy Followed by Adjuvant Chemotherapy With Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases

In this single-arm, phase II study, the authors evaluated the use of 3 months of adjuvant capecitabine plus oxaliplatin (CAPOX) following curative-intent resection of colorectal liver metastases in 28 patients. The 5-year recurrence-free and overall survival rates were 65% and 87%, respectively. The use of 3 months of adjuvant CAPOX Read more…

Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine Among Older and Frail Patients With Advanced Gastroesophageal Cancer

The authors of this multicenter, noninferiority, phase III trial evaluated the safety and efficacy of oxaliplatin and capecitabine in elderly frail patients with advanced gastroesophageal cancer. Oxaliplatin and capecitabine were dosed at level A, level B (80% of level A), or level C (60% of level A) in the chemotherapy-intensive Read more…